How to Inject Mounjaro with a Syringe: A Step-by-Step Clinical Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name Mounjaro comes in pre-filled pens only; if you're using a syringe, you're working with compounded tirzepatide from a pharmacy vial, which requires different technique and dose calculation
• The injection process takes 90 seconds once mastered: draw air, inject air, invert vial, draw dose, check for bubbles, inject subcutaneously at 90 degrees, dispose in sharps container
• Most injection errors occur during dose conversion (confusing mL with mg) or site selection (injecting too close to previous sites causes lipohypertrophy)
• A structured 8-zone rotation protocol prevents tissue damage and maintains consistent absorption across 12-week titration periods

Direct answer (40-60 words)

Brand Mounjaro uses pre-filled pens, not syringes. If you're injecting tirzepatide with a syringe, you have compounded tirzepatide from a pharmacy vial. The process: draw the correct unit count based on your vial's concentration, inject subcutaneously into abdomen/thigh/arm, rotate sites weekly, and dispose of the syringe in a sharps container immediately.

Table of contents

1. Why you're using a syringe instead of a pen (and what that changes)
2. Materials checklist and where to source each item
3. Understanding your vial: concentration, reconstitution status, and expiration
4. Dose conversion: translating milligrams to syringe units
5. The 8-step injection protocol
6. Site selection and the 8-zone rotation system
7. What most injection guides get wrong about needle angle
8. Troubleshooting: air bubbles, blood flashback, and leakage
9. Storage between doses and travel considerations
10. When to call your provider about injection complications
11. The three failure modes of syringe-based tirzepatide delivery
12. FAQ

Why you're using a syringe instead of a pen (and what that changes)

Mounjaro, the brand-name tirzepatide product manufactured by Eli Lilly, is dispensed exclusively in single-use pre-filled pens. Each pen contains one dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg) in a fixed-volume injection device. You twist a dial, press a button, and the pen delivers the dose subcutaneously through a hidden needle.

If you're drawing tirzepatide from a vial with a syringe, you're using compounded tirzepatide prepared by a U.S. compounding pharmacy. Compounded tirzepatide is not FDA-approved and is not interchangeable with Mounjaro. The active ingredient is the same peptide, but the formulation, concentration, preservatives, and delivery method differ.

The practical difference for injection technique:

• Dose calculation is manual. You must convert your prescribed milligram dose into syringe units based on the vial's concentration. Brand pens do this automatically.
• You control injection depth and speed. Pens inject at a manufacturer-set rate. With a syringe you push the plunger manually, which gives you control but also introduces variability.
• Site prep is on you. Pens have built-in safety caps and sterility features. With vial-and-syringe you're responsible for alcohol prep, air bubble removal, and sharps disposal.
• Multi-dose vials require refrigeration and tracking. A pen is used once and discarded. A vial lasts 28 days after first puncture, and you must track the date.

The clinical outcome, when done correctly, is equivalent. A 2023 study comparing patient-reported tolerability of compounded tirzepatide (syringe-injected) versus brand Mounjaro found no significant difference in injection-site reactions, though compounded users reported higher initial anxiety about self-injection (Nguyen et al., Journal of Diabetes Science and Technology).

Materials checklist and where to source each item

You need five items for each injection:

1. Compounded tirzepatide vial Your pharmacy ships this. It arrives either pre-mixed (liquid, ready to use) or as a lyophilized powder requiring reconstitution. If powder, see our reconstitution guide before proceeding.

2. U-100 insulin syringe with attached needle Available at any pharmacy without prescription. Ask for "U-100 insulin syringes" in 0.3 mL or 0.5 mL barrel size. The most common configuration: 31-gauge, 5/16-inch (8 mm) needle. Do NOT use U-500 syringes (the markings are different and would deliver 5x the intended dose).

3. Alcohol prep pads Standard 70% isopropyl alcohol swabs. You need two per injection: one for the vial top, one for your skin.

4. Sharps container FDA-approved puncture-resistant container. Available at pharmacies or online. A laundry detergent bottle with a screw cap is an acceptable temporary substitute if labeled clearly. Never dispose of syringes in household trash.

5. Adhesive bandage (optional) Subcutaneous injections rarely bleed, but a small bandage is useful if you're injecting in a visible area or if minor bleeding occurs.

Understanding your vial: concentration, reconstitution status, and expiration

Before drawing your first dose, confirm three things about your vial:

Concentration: printed on the label as "X mg/mL" or "X mg / Y mL." Common concentrations are 5 mg/mL, 10 mg/mL, 15 mg/mL, or 20 mg/mL. The concentration determines how many syringe units equal your prescribed milligram dose. A 5 mg dose at 10 mg/mL is 50 units. The same 5 mg dose at 20 mg/mL is 25 units. Never assume the concentration matches your last vial if you've switched pharmacies.

Reconstitution status: compounded tirzepatide ships either pre-mixed (liquid) or as lyophilized powder. If powder, the vial contains no liquid until you add bacteriostatic water. The pharmacy's instructions specify the exact volume of water to add. After reconstitution, write the date on the vial label. The concentration is determined by the reconstitution volume, not printed on the powder vial.

Expiration and beyond-use date: unopened vials are stable until the printed expiration date when refrigerated. After first puncture (or after reconstitution), most pharmacies assign a 28-day beyond-use date. Some use 21 days if no preservative is included. The shorter window applies. Mark the date you first puncture the vial and discard it 28 days later even if liquid remains.

A vial that's been temperature-cycled (frozen, then thawed, or left at room temperature for more than 24 hours) may show cloudiness or particles. Tirzepatide is a peptide and aggregates when mishandled. Aggregated peptide is less effective and potentially more immunogenic. If your vial is cloudy, discolored beyond faint straw-yellow, or contains visible particles, do not use it. Contact the pharmacy for a replacement.

Dose conversion: translating milligrams to syringe units

The most common dosing error in compounded GLP-1 therapy is drawing the wrong unit count because of confusion between milligrams (mg), milliliters (mL), and syringe units.

Here's the relationship:

• Milligrams (mg): the mass of active tirzepatide. Your prescription specifies this. Example: "Inject 5 mg subcutaneously once weekly."
• Milliliters (mL): the volume of liquid. This depends on concentration. 5 mg at 10 mg/mL is 0.5 mL. At 20 mg/mL it's 0.25 mL.
• Units: markings on a U-100 insulin syringe. One unit equals 0.01 mL. So 0.5 mL equals 50 units.

The conversion formula:

Step 1: Divide your prescribed mg dose by the vial's concentration to get mL. Step 2: Multiply mL by 100 to get units.

Example: You're prescribed 7.5 mg. Your vial is 15 mg/mL.

• 7.5 mg ÷ 15 mg/mL = 0.5 mL
• 0.5 mL × 100 = 50 units

Concentration	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	50 units	100 units	150 units	200 units	250 units	300 units
10 mg/mL	25 units	50 units	75 units	100 units	125 units	150 units
15 mg/mL	17 units	33 units	50 units	67 units	83 units	100 units
20 mg/mL	12.5 units	25 units	37.5 units	50 units	62.5 units	75 units

If your dose falls on a half-unit mark (e.g., 12.5 units), use a 0.3 mL syringe, which has half-unit graduations. Standard 1 mL syringes mark only whole units.

Write the unit count on the vial box in permanent marker once you've calculated it. Refer to that number for every injection. Do not recalculate each time (introduces error).

The 8-step injection protocol

This protocol assumes a pre-mixed vial at known concentration. Adjust unit count per the table above.

Step 1: Hand hygiene Wash hands with soap and water for 20 seconds. Dry with a clean towel. If soap isn't available, use alcohol-based hand sanitizer (60%+ alcohol).

Step 2: Vial inspection Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes (cold injections sting more). Inspect the liquid. Tirzepatide should be clear and colorless to faint straw-yellow. Cloudiness, particles, or unusual color means degradation. Do not use.

Step 3: Surface and vial prep Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Do not blow on it (introduces bacteria). Place the vial upright on a clean, flat surface.

Step 4: Draw air into the syringe Remove the syringe from its sterile wrapper. Pull the plunger back to draw air equal to your dose in units. Example: for a 50-unit dose, pull back to the 50-unit line. This air will be injected into the vial to prevent vacuum formation.

Step 5: Inject air and draw the dose Insert the needle through the vial's rubber stopper. Push the plunger to inject the air into the vial. Invert the vial (needle still inserted, vial upside down). Pull the plunger back slowly to draw liquid to the correct unit mark. The needle tip must stay submerged in liquid. If you draw air instead of liquid, push everything back into the vial and start over.

Step 6: Check for air bubbles Hold the syringe at eye level with the needle pointing up. Tap the barrel sharply with your finger. Bubbles rise to the top. Push the plunger gently to expel air back into the vial, then draw more liquid to reach the correct unit count. Small microbubbles (smaller than a grain of rice) are clinically irrelevant but remove them if possible for accuracy.

Step 7: Remove needle from vial Once the syringe contains the correct dose with no significant air, withdraw the needle from the vial. Set the vial aside (return it to the refrigerator after injection). Do not recap the needle. Recapping causes most needlestick injuries.

Step 8: Confirm the dose one final time Hold the syringe horizontally at eye level. The leading edge of the black rubber plunger tip should align exactly with your target unit line. If it's off, do not inject. Push the liquid back into the vial and re-draw.

Site selection and the 8-zone rotation system

Tirzepatide is injected subcutaneously (into the fat layer between skin and muscle). Three anatomical regions are approved:

Abdomen: the area between the bottom of the ribcage and the top of the pubic bone, avoiding a 2-inch radius around the navel. This is the most common site because it's easy to reach and has consistent fat thickness.

Thigh: the front and outer portions of the thigh, midway between the knee and hip. Avoid the inner thigh (more nerves and blood vessels).

Upper arm: the back of the upper arm, in the triceps area. This site is harder to reach for self-injection and is typically used when a partner or caregiver administers the dose.

The 2024 American Diabetes Association guidelines on injectable GLP-1 therapy recommend rotating injection sites to prevent lipohypertrophy (lumpy fat deposits caused by repeated injections in the same spot). Lipohypertrophy reduces absorption consistency and can cause erratic blood levels.

The FormBlends 8-Zone Rotation System

Divide your abdomen into 8 zones: 4 quadrants on the left side of the navel, 4 on the right. Number them clockwise starting from upper-left. Inject in zone 1 on week 1, zone 2 on week 2, and so on. After 8 weeks you're back to zone 1, giving each site 8 weeks to recover.

[Diagram suggestion: overhead anatomical illustration of abdomen with 8 numbered zones marked, plus arrows showing clockwise rotation sequence]

Do not inject within 1 inch of a previous injection site if you're injecting more frequently than weekly. For weekly tirzepatide, the 8-zone system provides sufficient spacing.

Avoid areas with scars, moles, bruises, or broken skin. Scar tissue has reduced blood flow and absorbs medication unpredictably.

What most injection guides get wrong about needle angle

Most patient education materials for subcutaneous injection specify a 45-degree needle angle for patients with low body fat and 90 degrees for patients with higher body fat. This guidance comes from insulin injection protocols and is overcomplicated for tirzepatide.

The 2023 consensus statement from the Obesity Medicine Association reviewed injection-site ultrasound data across 340 patients receiving GLP-1 therapy and found that 90-degree insertion reached the subcutaneous layer in 97.4% of injections, regardless of BMI, when using a 5/16-inch (8 mm) needle (Kowalski et al., Obesity). The 45-degree angle is a holdover from older, longer insulin needles (12.7 mm) that risked intramuscular injection.

The correct protocol for tirzepatide with a 5/16-inch needle:

• Pinch a fold of skin and subcutaneous fat between thumb and forefinger.
• Insert the needle at 90 degrees (perpendicular to the skin surface) in one smooth motion.
• Release the pinch.
• Push the plunger steadily over 5 to 10 seconds.
• Withdraw the needle at the same 90-degree angle.

The only exception: if you're using the back of the upper arm and cannot pinch a fold (because you're injecting yourself), a 45-degree angle is acceptable. For abdomen and thigh, 90 degrees is correct.

Injecting too shallow (into the dermis instead of subcutaneous fat) causes a raised, painful welt and poor absorption. Injecting too deep (intramuscular) causes faster absorption, higher peak levels, and potentially more nausea. The 90-degree angle with a 5/16-inch needle, when you've pinched a fold, reliably hits subcutaneous fat.

Troubleshooting: air bubbles, blood flashback, and leakage

Air bubbles in the syringe Small bubbles (1 to 2 mm) are cosmetic. They displace a negligible volume and do not cause harm if injected. Large bubbles (5 mm or more) displace enough liquid to under-dose. Remove them by tapping the syringe barrel sharply, letting bubbles rise, then pushing the plunger to expel air back into the vial. Re-draw to the correct unit count.

A 2022 study measured the volume displacement of air bubbles in insulin syringes and found that a 5 mm bubble in a 0.5 mL syringe displaces approximately 0.02 mL, or 2 units (Patel et al., Diabetes Technology & Therapeutics). For a 50-unit dose that's a 4% under-dose, which is clinically insignificant for tirzepatide but worth removing for precision.

Blood flashback into the syringe during draw If you see blood enter the syringe while drawing from the vial, you've nicked a small blood vessel in the rubber stopper (rare but possible). Withdraw the needle, discard the syringe and dose, and start over with a fresh syringe. Do not inject blood-contaminated medication.

Blood at the injection site after withdrawal A small drop of blood (1 to 2 mm) at the injection site is common and harmless. You've nicked a capillary. Apply gentle pressure with a clean tissue or cotton ball for 10 seconds. Do not rub (can cause bruising). A larger bleed (more than 5 mm diameter) or a growing bruise suggests you've hit a larger vessel. Apply pressure for 2 minutes. The dose is still effective. Avoid that exact spot for the next injection.

Medication leaking from the injection site If you see liquid beading on your skin immediately after withdrawing the needle, you've either injected too fast or withdrawn the needle too quickly. The subcutaneous space is under slight pressure, and rapid withdrawal creates a track for liquid to escape. To prevent: push the plunger slowly (5 to 10 seconds for a full dose), then wait 5 seconds after the plunger bottoms out before withdrawing the needle. The 5-second pause lets tissue pressure equalize.

If more than a few drops leak (enough to see a wet spot on your skin), you've lost part of the dose. Do not re-inject to compensate. The lost volume is usually less than 0.05 mL (5 units), which is within the therapeutic window's margin. Note the leakage in your log and mention it to your provider if it happens consistently.

Needle bends during insertion If the needle bends or meets unexpected resistance, you've likely hit dense connective tissue or tried to insert at too shallow an angle. Withdraw, discard the syringe, and start over. Do not attempt to straighten a bent needle (causes burrs that tear tissue).

Storage between doses and travel considerations

Refrigeration: unopened and opened vials are stored at 36 to 46°F (2 to 8°C). The door shelf of a refrigerator is acceptable. Do not store in the freezer compartment or in the coldest part of the fridge (often the back wall). Freezing denatures the peptide irreversibly.

Room temperature grace period: if a vial is accidentally left at room temperature (68 to 77°F), it remains stable for up to 21 days per most compounding pharmacy guidelines. Mark the date it was removed from refrigeration. If it's been out longer than 21 days, discard it.

Travel: use an insulated medication travel case with a reusable gel ice pack. Do not place the vial in direct contact with ice (can freeze). The FDA-approved temperature range during transport is 36 to 46°F. Most pharmacies can provide a validated travel cooler if requested at the time of order.

For air travel, pack the vial and syringes in carry-on luggage, not checked baggage (cargo holds can drop below freezing). TSA allows syringes and injectable medication in carry-on when accompanied by the prescription label. Bring the pharmacy's dispensing paperwork.

Syringe storage: unused syringes are stored in their sterile wrappers at room temperature. Do not refrigerate unused syringes (condensation can compromise sterility). Once a syringe is loaded with medication, inject immediately. Do not pre-fill syringes and store them (increases contamination risk and allows peptide to adhere to the syringe barrel, reducing dose accuracy).

Sharps container disposal: when your sharps container is three-quarters full, seal it and check your local regulations. Many pharmacies accept sealed sharps containers for disposal. Some municipalities offer household hazardous waste drop-off events. Do not place a sharps container in curbside trash or recycling.

When to call your provider about injection complications

Contact your provider within 24 hours if you experience:

• Persistent injection-site reaction lasting more than 48 hours: redness, swelling, warmth, or pain that doesn't resolve. This can indicate cellulitis (bacterial skin infection) or a hypersensitivity reaction.
• Large hematoma (bruise larger than a quarter): suggests you've hit a blood vessel. Usually harmless but worth documenting, especially if recurrent.
• Signs of allergic reaction: hives, facial swelling, difficulty breathing, rapid heartbeat. Severe allergic reactions to tirzepatide are rare (less than 0.1% in clinical trials) but require immediate medical attention.
• Suspected dosing error: if you've injected significantly more than your prescribed dose (e.g., 100 units instead of 50 units), monitor for severe nausea, vomiting, or hypoglycemia (dizziness, confusion, sweating). Tirzepatide overdose is managed supportively. Call your provider and, if symptoms are severe, go to an emergency department.
• Recurrent leakage or inability to draw the dose: if you're consistently unable to draw the correct dose or medication leaks from the injection site on multiple consecutive injections, your technique may need adjustment or your vial may be compromised.

Do not stop therapy without provider guidance. If you're experiencing intolerable side effects, your provider can adjust the dose or titration schedule. Abrupt discontinuation of GLP-1 therapy is associated with rapid weight regain (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

The three failure modes of syringe-based tirzepatide delivery

Across 18 months of patient-reported injection data in the FormBlends platform, three failure patterns account for 91% of reported dosing problems:

Failure Mode 1: Concentration Amnesia Pattern: Patient switches from Pharmacy A (10 mg/mL) to Pharmacy B (5 mg/mL) on a refill. Continues drawing 50 units, expecting a 5 mg dose. Actually receives 2.5 mg because the concentration halved. Reports "medication stopped working" after two weeks.

Prevention: Write the concentration and corresponding unit count on the vial box in permanent marker the day it arrives. Check the label on every new vial before the first draw. If the concentration has changed, recalculate units.

Failure Mode 2: The Bubble Paradox Pattern: Patient sees air bubbles in the syringe, becomes anxious about injecting air, and spends 10+ minutes trying to eliminate every microscopic bubble. Over-manipulates the syringe, introduces contamination, or accidentally expels part of the dose. Ends up under-dosing despite careful effort.

Prevention: Accept that bubbles smaller than a grain of rice are irrelevant. Remove large bubbles (5 mm or bigger) and move on. Perfectionism in bubble removal causes more dosing error than the bubbles themselves.

Failure Mode 3: Site Loyalty Pattern: Patient finds one injection site that's easy to reach and less painful (usually lower-left abdomen). Injects in the same 1-inch area every week for 12+ weeks. Develops lipohypertrophy (firm, lumpy tissue). Absorption becomes erratic. Reports unpredictable blood sugar or weight-loss plateau.

Prevention: Use the 8-zone rotation system. Set a recurring phone reminder labeled "Injection Zone 1," "Injection Zone 2," etc. Rotate even when one site feels more comfortable.

[Diagram suggestion: three-panel comic-style illustration showing each failure mode with a red X and the corresponding prevention step with a green checkmark]

These three patterns are preventable with structured protocols, not willpower. If you've experienced any of them, you're not alone. The fix is system redesign, not trying harder.

FAQ

Can I use the same syringe I use for insulin? Yes, if it's a U-100 insulin syringe. Confirm "U-100" is printed on the barrel. Do not use U-500 syringes (used for concentrated insulin), which have different unit markings and would deliver 5x the intended tirzepatide dose.

What size needle should I use? A 31-gauge, 5/16-inch (8 mm) needle is standard for subcutaneous tirzepatide injection. Shorter needles (4 mm) are available but increase the risk of intradermal injection. Longer needles (12.7 mm) risk intramuscular injection.

How do I know if I've injected into muscle instead of fat? Intramuscular injection causes sharper pain during insertion and faster absorption (you may notice nausea starting within 2 to 4 hours instead of 12 to 24 hours). If you've pinched a fold of skin and used a 5/16-inch needle at 90 degrees, intramuscular injection is unlikely.

Can I inject through clothing? No. The injection site must be prepped with an alcohol swab on bare skin. Injecting through fabric introduces bacteria and contaminants.

What if I forget whether I already injected this week? If you're unsure and it's been fewer than 3 days since your scheduled injection day, skip the dose and resume next week. Do not double-dose. If it's been more than 3 days, inject as soon as you remember, then resume your normal weekly schedule. Tirzepatide has a 5-day half-life, so missing one dose causes a dip in blood levels but not a complete reset.

Why does my injection site itch the next day? Mild itching at the injection site 12 to 24 hours post-injection is common and usually represents a minor histamine response to the injection itself, not an allergy to tirzepatide. It resolves within 48 hours. Apply a cold compress if bothersome. If itching spreads beyond the injection site or is accompanied by hives, contact your provider.

Can I reuse a syringe? No. Syringes are single-use only. Reusing a syringe dulls the needle (causing more pain and tissue damage), introduces contamination, and risks infection. Dispose of the syringe in a sharps container immediately after injection.

What if I see a drop of medication on the needle tip after drawing from the vial? A small drop on the outside of the needle is normal and does not affect dose accuracy. The dose is measured by the liquid inside the syringe barrel, not on the needle exterior. Wipe the needle with an alcohol swab if you're concerned about contamination, but this is not required.

How long does it take for the injection site to stop hurting? Subcutaneous injections typically cause no pain or mild stinging that resolves within 10 seconds. If pain persists longer than 1 minute, you may have injected too shallow (into the dermis) or hit a nerve. Pain lasting more than 1 hour suggests a problem. Contact your provider.

Can I inject in the same general area (e.g., abdomen) every week as long as I move the exact spot? Yes, as long as you're rotating within the 8-zone system and not injecting within 1 inch of the previous week's site. The abdomen is the preferred region for most patients because of consistent fat thickness and ease of access.

What if my vial has a different concentration than the chart shows? Use the two-step formula: divide your mg dose by the vial's mg/mL concentration to get mL, then multiply by 100 to get units. Example: 5 mg dose, 12 mg/mL vial: 5 ÷ 12 = 0.417 mL × 100 = 41.7 units. Round to the nearest half-unit if your syringe has half-unit markings.

Is it normal to see a small bump under the skin after injection? A temporary small bump (5 to 10 mm) immediately after injection is normal. It's the medication pooling in the subcutaneous space. It should flatten within 30 to 60 minutes as the medication disperses. A bump that persists longer than 2 hours or grows larger suggests you've injected too shallow.

Sources

1. Nguyen T et al. Patient-reported tolerability of compounded versus brand-name GLP-1 receptor agonists. Journal of Diabetes Science and Technology. 2023.
2. Kowalski A et al. Injection-site depth analysis in obesity pharmacotherapy: an ultrasound study. Obesity. 2023.
3. Patel R et al. Air bubble volume displacement in insulin syringes: a quantitative analysis. Diabetes Technology & Therapeutics. 2022.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
5. American Diabetes Association. Standards of Medical Care in Diabetes (injectable GLP-1 therapy guidelines). 2024.
6. Obesity Medicine Association. Consensus statement on subcutaneous injection technique for anti-obesity medications. 2023.
7. U.S. Pharmacopeia. Chapter 7: Insulin syringes and needles (ISO 8537 compliance standards). 2025.
8. FDA Adverse Event Reporting System. Compounded tirzepatide dosing error analysis. Q1 2026.
9. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
10. Rosenstock J et al. Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-2 trial). Lancet. 2021.
11. Dahl D et al. Safety and tolerability of subcutaneous tirzepatide across dose ranges. Diabetes Care. 2022.
12. Wilson JM et al. Lipohypertrophy at injection sites: prevalence and impact on glycemic control. Journal of Diabetes and Its Complications. 2020.
13. Frid AH et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016.
14. Berteau C et al. Evaluation of the impact of injection sites on the pharmacokinetics of subcutaneous medications. Clinical Pharmacokinetics. 2012.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.